Ozempic's biggest side effect: Turning Denmark into a 'pharmastate'?
Ozempic and similar GLP‑1 weight‑loss drugs are generating explosive demand and profits, to the point that Denmark’s Novo Nordisk now dominates the country’s economy and tax base. Commenters weigh the benefits of these medicines for obesity, diabetes and possibly other conditions against concerns over high prices, supply bottlenecks, long‑term safety and dependence on a single pharma giant. They also debate broader issues such as personal responsibility versus biology in obesity, the ethics of using stimulants like Adderall for weight control, and how impending competition and generics could reshape the market.
Economics, Supply & Competition
- Demand for Ozempic/Wegovy is seen as supply‑constrained; many claim “everyone” wants it, but starter doses are hard to get and pharmacies worry about ongoing supply.
- Some argue scarcity is driven by injector‑pen manufacturing, not the active ingredient, and suspect intentional scarcity since vials plus standard syringes are possible.
- Debate over pricing: some see current price as profit‑maximizing under limited supply; others note prices should fall as capacity and competition grow.
- Patents are expected to expire within a decade; commenters expect a “massive” wave of generics and rival GLP‑1 drugs that should push prices down.
- Many biotechs reportedly have GLP‑1 or multi‑agonist (dual/triple) obesity drugs in the pipeline, some aiming for oral forms and greater efficacy.
Access, Compounding & Counterfeits
- Some users obtain semaglutide from compounding pharmacies via telehealth for ~$200–400/month, typically in multi‑dose vials.
- There is concern about variable quality (e.g., “salt semaglutide”), dosing errors, and reliance on short‑supply exemptions.
- Reports of easy OTC access in places like Mexico are met with skepticism due to counterfeit risks and inconsistent quality in tourist‑focused pharmacies.
Alternatives: Stimulants vs GLP‑1
- Several compare GLP‑1 drugs to Adderall/phentermine for weight loss.
- Stimulants suppress appetite and improve ADHD symptoms for some, but many note tolerance, intense side effects, high addiction/psychosis and cardiovascular risk, and historical withdrawal of amphetamine weight‑loss drugs.
- GLP‑1 agonists are seen as more appropriate for obesity because of better risk/benefit in trials and lack of controlled‑substance issues.
Health Effects, Use Cases & Long‑Term Role
- People at healthy BMI ask about benefits; speculative mentions include possible neuroprotective effects and ADHD help, but evidence is described as early or n=1.
- Many emphasize GLP‑1s change hunger/satiety and relationship with food rather than being a “fire‑and‑forget” fix.
- One view: Ozempic is not a true long‑term solution; diet, nutrition education, and monitoring are.
Obesity, Willpower & Environment
- Strong divide: some frame obesity largely as lack of willpower and gluttony; others argue this is judgmental and ignores biology, environment, and ultra‑processed food engineering.
- Cited evidence/claims include links between obesity and geography/altitude, pollution, cheap energy‑dense foods, and food deserts; critics counter with examples of affordable healthy diets, especially in Europe.
- Debate over whether drugs like Ozempic are a “band‑aid” versus legitimate therapy that effectively raises “willpower” for those who lack it.
Denmark, Novo Nordisk & “Pharmastate” Concerns
- Novo Nordisk is portrayed as extraordinarily large and central to Denmark’s economy, paying huge domestic taxes and being foundation‑owned, which may reduce tax‑avoidance incentives.
- Some see media claims that the company “saved Denmark from recession” as overstated and note that labor is fungible; in a different sector it might have produced equal or greater value.
- Others point out the firm’s dominance makes growing alternative Danish champions difficult, raising concerns about economic concentration.